Movement Disorders
AAN 2026 highlights: key trial updates across narcolepsy, movement disorders, Tourette syndrome & more!
This episode of the VJNeurology Podcast showcases key trial updates from the American Academy of Neurology Annual Meeting in Chicago,…
Date: 5th May 2026
Gene therapy in Parkinson’s disease and other neurological disorders: advances and future directions
In this episode of the VJNeurology Podcast, we’re joined by Krystof Bankiewicz, MD, PhD, The Ohio State University, Columbus, OH,…
Date: 6th August 2025
Artificial intelligence: a new era in neurology
The integration of artificial intelligence (AI) into the field of neurology has opened the door to unprecedented advancements. From facilitating…
Date: 9th August 2023
The wearables revolution in neurology
Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients’ neurological conditions. From…
Date: 2nd August 2023
α-syn in Parkinson’s disease: cause, biomarker, and treatment target
The causative nature of alpha-synuclein (α-syn) accumulation in Parkinson’s disease pathophysiology has been a subject of debate among researchers, ever…
Date: 25th July 2023
Emerging treatment approaches for Parkinson’s disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and thus far, only efficacious symptomatic treatments have been developed,…
Date: 3rd February 2023
Key trials in Huntington’s disease: SAGE-718, pridopidine, PTC518, & ANX005
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG expansion in the huntingtin (HTT) gene. The…
Date: 19th October 2022
New horizons in hyperkinetic movement disorders
Hyperkinetic movement disorders (HMDs) are characterized by the presence of excessive, abnormal, and involuntary movements and can be isolated or…
Date: 13th October 2022
Novel targets for therapeutic intervention in movement disorders
The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement…
Date: 30th September 2022
Latest developments in the treatment of motor fluctuations in Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world. This high prevalence of PD has put…
Date: 8th July 2022
Updates in isolated RBD
Isolated RBD (iRBD) has been established as REM sleep behavior disorder without an associated neurodegenerative condition. However, RBD is commonly…
Date: 11th May 2022
Subtyping in Parkinson’s disease
It is well recognized that Parkinson’s disease (PD) can present with a broad spectrum of motor and non-motor symptoms, and…
Date: 2nd February 2022
